S. 1269 · 118th Congress (2023–2025)
INSULIN Act of 2023
This bill limits cost-sharing for insulin under private health insurance and revises the requirements for approval and cost-sharing of generic drugs and biosimilar products.
Specifically, the bill caps cost-sharing under private health insurance for a month's supply of selected insulin products at $35 or 25% of a plan's negotiated price (after any price concessions), whichever is less, beginning in 2025.
The bill also requires pharmacy benefit managers (PBMs) to remit to the group health plan 100% of the fees, alternative discounts, and all other remuneration received from a drug manufacturer.
Additionally, the bill modifies the Food and Drug Administration's (FDA) procedures for determining whether a petition to delay the approval of a generic drug was made with the primary purpose of delaying the application and provides for the referral of such petitions to the Federal Trade Commission. The bill also authorizes the FDA to expedite the development and review of applications for products designated as a competitive biosimilar therapy.
Finally, the bill permits prescription drug plan sponsors under Medicare Part D to make certain mid-year changes to the cost-sharing tier of a reference biological product if the sponsor also adds the respective biosimilar product to the same or a lower cost-sharing tier as the reference biological product immediately prior to the change.
Show official title
A bill to reduce the price of insulin and provide for patient protections with respect to the cost of insulin.
Expired in Senate committee
Derived from the legislative history, not an official disposition.
Latest actionReferred to committee
This bill’s path
This is S. 1269’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced
Passed Senate
Passed House
Sent to President
Signed into law
Expired
- Sponsor
- Sen. Jeanne Shaheen (D-NH)
- Cosponsors
13 cosponsors
1 original · 12 later
7 R · 5 D · 1 I
- Sen. Susan M. Collins (R-ME)· Original · Apr 25, 2023
- Sen. Katie Boyd Britt (R-AL)· Later · Jun 22, 2023
- Sen. Debbie Stabenow (D-MI)· Later · Jun 22, 2023
- Sen. Tommy Tuberville (R-AL)· Later · Jun 22, 2023
- Sen. Jon Tester (D-MT)· Later · Jun 22, 2023
- Sen. Mark Kelly (D-AZ)· Later · Sep 19, 2023
- Sen. Roger F. Wicker (R-MS)· Later · Sep 19, 2023
- Sen. Lisa Murkowski (R-AK)· Later · Oct 4, 2023
- Sen. Jacky Rosen (D-NV)· Later · Oct 4, 2023
- Sen. Mike Braun (R-IN)· Later · Nov 2, 2023
- Sen. Angus S. King Jr. (I-ME)· Later · Nov 2, 2023
- Sen. Tammy Baldwin (D-WI)· Later · Nov 9, 2023
- Sen. Chuck Grassley (R-IA)· Later · Nov 9, 2023
- Policy area
- Health
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Introduced in Senate
Document: Introduced in Senate
Sources
- Congress.gov action
- Library of Congress
- Latest
Referred to committee
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sources
- Congress.gov action
- Senate
Expired
Introduced → Referred to Senate Health, Education, Labor, and Pensions → No further action before the 118th Congress ended.
Committees
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
| Version | Date | Links |
|---|---|---|
| Introduced in Senate |
Titles (3)
INSULIN Act of 2023
Display title, Short title · Introduced in Senate
Improving Needed Safeguards for Users of Lifesaving Insulin Now Act of 2023
Short title · Introduced in Senate
A bill to reduce the price of insulin and provide for patient protections with respect to the cost of insulin.
Official title · Introduced in Senate